Journal of Research & Health (May 2024)

Risk Score Model for Predicting COVID-19 Progression in Iranian Patients: Development and Validation Study

  • Fatemeh Mohammadzadeh,
  • Ali Delshad Noughabi,
  • Sina Sabeti Bilondi,
  • Mitra Tavakolizadeh,
  • Jafar Hajavi,
  • Hosein Aalami,
  • Mohsen Sahebanmaleki

Journal volume & issue
Vol. 14, no. 3
pp. 217 – 230

Abstract

Read online

Background: The recent novel coronavirus disease 2019 (COVID-19) pandemic has underlined the importance of risk score models in public health emergencies. This study aimed to develop a risk prediction score to identify high-risk hospitalized patients for disease progression on admission. Methods: This prospective cohort study included 171 COVID-19 patients, identified through the reverse transcription polymerase chain reaction test, admitted to Bohlool Hospital in Gonabad City, Iran, between April 4 and June 5, 2021. The patients’ demographic, clinical, and laboratory data were collected upon admission, and clinical outcomes were monitored until the end of the study. The discovery dataset (80% of the data) was used to develop the risk score model based on clinical and laboratory features and patient characteristics to predict COVID-19 progression. An additive risk score model was developed based on the regression coefficients of the significant variables in a multiple logistic regression model. The performance of the risk score model was evaluated on the validation dataset (20% of the data) using the receiver operating characteristic (ROC) curve. Statistical analyses were performed with SPSS software, version 21. Results: The Mean±SD for age of participants was 59.54±20.52 years, and 48.6% were male. Most patients (82.5%) fully recovered or showed improvement, while 5.2% experienced disease progression and 12.3% died. Three variables, interleukin-6, neutrophil-to-lymphocyte ratio, and lung involvement, were found to be significant in predicting risk, with a good discriminatory ability, having an area under the ROC curve of 0.970 (95% CI, 0.935%, 1.00%) in the discovery set and 0.973 (95% CI, 0.923%, 1.00%) in the validation set. Conclusion: The developed risk score model in this study can be used as a clinical diagnostic tool to identify COVID-19 patients at higher risk of disease progression and aid in informed decision-making and resource utilization in similar situations, such as respiratory disease outbreaks in the post-corona era.

Keywords